General
Preferred name
Omidenepag isopropyl
Synonyms
DE-117 ()
DE117 ()
DE 117 ()
Omlonti ()
P&D ID
PD122251
CAS
1187451-19-9
Tags
available
drug
prodrug
Approved by
PMDA
FDA
First approval
2018
2022
Drug indication
Glaucoma/ocular hypertension
Open-angle glaucoma
Drug Status
investigational
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Omidenepag isopropyl is a selective EP2 receptor agonist. Omidenepag isopropyl is converted to the active product Omidenepag during corneal penetration, and Omidenepag is a highly selective EP2 receptor agonist. Omidenepag isopropyl shows only weak affinity for EP1, EP2, and FP receptors. Omidenepag isopropyl is under development for the treatment of glaucoma as an intraocular pressure (IOP)-lowering agent.
PRICE 205
DESCRIPTION Omidenepag isopropyl (DE-117) is a selective prostaglandin EP2 receptor agonist and a novel topical ocular blood pressure lowering compound.Omidenepag isopropyl has a weak affinity for EP1, EP2, and FP receptors.Omidenepag isopropyl is used in studies of glaucoma and hypertension. Omidenepag isopropyl can be used to study glaucoma and hypertension. (TargetMol Bioactive Compound Library)
Compound Sets
11
Cayman Chemical Bioactives
41046
ChEMBL Approved Drugs
CHEMBL4297666
ChEMBL Drugs
CHEMBL4297666
DrugBank
DB15071
DrugBank Approved Drugs
DB15071
DrugCentral
5312
DrugCentral Approved Drugs
5312
DrugMAP
DMUX7Z8
MedChem Express Bioactive Compound Library
HY-111406
ReFrame library
TargetMol Bioactive Compound Library
T16388
External IDs
15
Properties
(calculated by RDKit )
Molecular Weight
520.19
Hydrogen Bond Acceptors
9
Hydrogen Bond Donors
1
Rotatable Bonds
11
Ring Count
4
Aromatic Ring Count
4
cLogP
3.42
TPSA
119.31
Fraction CSP3
0.23
Chiral centers
0.0
Largest ring
6.0
QED
0.3
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
EP2
EP1
Prostaglandin Receptor
Pathway
GPCR/G protein
Immunology/Inflammation
Source data